Skip to content
Screener

PTC Therapeutics PTCT Business Segments — Depreciation

Similar metrics at other companies

Revvity logo
RVTYLife Sciences — Depreciation
$9.91M+37.9%
Ashland logo
ASHLife Sciences — Depreciation
$10M-41.2%
Agilent Technologies logo
ALife Sciences and Diagnostics Markets — Depreciation
$26M+8.3%
Sunbelt Rentals Holdings logo
SUNBSpecialty — Depreciation
$141M+6.0%
Sunbelt Rentals Holdings logo
SUNBU.K. — Depreciation
$43M+2.4%
Cato Corporation logo
CATOCredit — Depreciation
$0

Other financials

Income statement

See full
Revenue$272.6M-76.8%
Operating income$45.0M-95.4%
Net income-$2.8M-100%
EPS (diluted)-$0.03-100%

Balance sheet

See full
Cash & equivalents$834.0M-43.7%
Total debt$395.1M+0.1%
Total equity-$180.5M+2.9%
Total assets$2.9B+8.0%

Cash flow

See full
Operating cash flow-$59.0M-107%
CapEx$1.2M-30.6%
Free cash flow-$60.2M-107%

Valuation

See full
Market cap$5.78B+41.9%
Enterprise value$5.34B+54.9%
P/E7.1×
P/S+4.7×

Profitability

See full
Gross margin96%
Operating margin1.6%-38.7pp
Net margin42.3%+27.4pp
FCF margin39.1%+32.8pp

Returns & leverage

See full
Return on equity-216.7%
Debt / equity372.3×
Current ratio2.4×-1.5×

Where this comes from

Reported directly by PTC Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The source filing: PTC Therapeutics’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:32 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001070081-26-000012
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Interest income$$(17,985)(17,245)
Interest expense67,01551,337
Income tax expense34763,266
Depreciation3,8063,458
Amortization11,5813,798
All other (b)43,12540,809
Total other segment items$$107,889145,423

Item 1. Financial Statements (unaudited)

FAQ

What is PTC Therapeutics's business segments — depreciation?
PTC Therapeutics (PTCT) reported business segments — depreciation of $3.81M in Q1 2026.
How has PTC Therapeutics's business segments — depreciation changed year-over-year?
PTC Therapeutics's business segments — depreciation increased by 10.1% year-over-year, from $3.46M to $3.81M.
What is the long-term trend for PTC Therapeutics's business segments — depreciation?
Over 2 years (2023 to 2025), PTC Therapeutics's business segments — depreciation has grown at a 0.9% compound annual growth rate (CAGR), from $13.95M to $14.2M.
What does business segments — depreciation mean?
This metric represents the systematic allocation of the cost of tangible assets over their useful lives within the Life Science segment. It is a non-cash expense that reflects the wear and tear or obsolescence of physical infrastructure, such as laboratory equipment and facilities. Tracking this metric is essential for understanding the segment's capital intensity and the ongoing reinvestment required to maintain operational capacity.

Ask your AI about PTC Therapeutics's business segments — depreciation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude